A DNA vaccine for the prevention of Ebola virus infection.
The NIH and Vical Inc are developing an intramuscular needle-free DNA vaccine containing plasmids encoding the envelope glycoprotein of Ebola virus (EBOV) from the Sudan and Zaire strains, and the nucleoprotein of EBOV Zaire strain. A phase I clinical trial demonstrated a good safety profile, with most adverse events limited to the site of injection and largely attributable to the delivery.
Tulane University Health Sciences Center, Department of Medicine, Infectious Diseases Section, 1430 Tulane Ave SL-87, New Orleans, LA 70112-2699, USA. madery@tulane.edu
Markalain
M
Dery
Daniel G
DG
Bausch
D002986:Clinical Trials as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D046129:Ebola Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D013329:Structure-Activity Relationship; D019444:Vaccines, DNA / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics
D046129:Ebola Vaccines; D019444:Vaccines, DNA